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Abstract 
Background: Negative pressure wound therapy (NPWT) is increasingly used 
prophylactically following surgery despite limited evidence of clinical or cost-effectiveness.  
Objective: To evaluate whether NPWT is cost-effective compared to standard care, for the 
prevention of surgical site infection (SSI) in obese women undergoing elective caesarean 
section, and inform development of a larger trial.  
Methods: An economic evaluation was conducted alongside a pilot randomised controlled 
trial at one Australian hospital,  in which women were randomised to NPWT (n=44) or 
standard care (n=43). A public health care provider perspective and time horizon to four 
weeks post-discharge was adopted. Cost-effectiveness assessment was based on incremental 
cost per SSI prevented and per quality-adjusted life year (QALY) gained. 
Results: Patients receiving NPWT each received health care costing AU$5,887 (±1,038) and 
reported 0.069 (±0.010) QALYs compared to AU$5,754 (±1,484) and 0.066 (±0.010) 
QALYs for patients receiving standard care. NPWT may be slightly more costly and more 
effective than standard care, with estimated incremental cost-effectiveness ratios (ICERs) of 
AU$1,347 (95%CI dominant- $17,666) per SSI prevented and AU$42,340 (95%CI 
dominant- $884,019) per QALY gained. However, there was considerable uncertainty around 
these estimates which did not reach significance. 
Conclusions: NPWT may be cost-effective in the prophylactic treatment of surgical wounds 
following elective caesarean section in obese women. Larger trials are could clarify the cost-
effectiveness of NPWT as a prophylactic treatment for SSI. Sensitive capture of QALYs and 
cost offsets will be important given the high level of uncertainty around the point estimate 
cost-effectiveness ratio which was close to conventional thresholds. 
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1.0 Introduction 
Surgical site infection (SSI) is the third most commonly reported type of hospital-acquired 
infection, and a major impediment to surgical wound healing [1]. SSIs can cause higher 
resource use (and hence higher healthcare costs), patient distress and poor physical, 
emotional or economic outcomes [2]. Thus, SSI prevention is an important perioperative care 
objective. 
Negative pressure wound therapy (NPWT) was developed in the 1990s to aid wound healing 
[3] and is increasingly used prophylactically to prevent wound complications, including SSIs, 
particularly in obese patients or those with difficult-to-heal wounds [4]. This is despite a lack 
of understanding about the mechanisms by which NPWT aids wound healing (experimental 
evidence suggests several factors may be involved [3]) and limited evidence of efficacy [4]. 
There have been a number of reviews of NPWT [4-8] , with some favouring NPWT over 
standard dressings [5, 6] and others failing to find convincing evidence of benefit [4, 7, 8]. 
The majority of these focus either primarily or entirely on studies of NPWT in the treatment 
setting [5-8], although a Cochrane review of NPWT for prophylactic postoperative use 
concluded that the evidence for effectiveness was unclear [4]. 
The cost-effectiveness of NPWT is also unclear. One study developed a decision model 
combining information from the literature with data from a small pilot study and professional 
assessments [9, 10]. The authors concluded that NPWT achieves lower overall costs and 
superior outcomes compared to standard treatment for severe pressure ulcers [9, 10]. Other 
researchers have concluded that NPWT is cost-effective compared to standard treatment in 
retrospective chart reviews [11] and comparative case-studies [12]. The results of these 
studies are highly uncertain and generalisability is limited by the heterogeneity of patients 
receiving NPWT [6]. Additionally, most cost-effectiveness studies have focused on the 
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treatment of chronic, difficult-to-heal wounds [6, 10, 11]. NPWT is increasingly used 
prophylactically following surgery for high-risk clean wounds [13], particularly in obese 
patients at greater risk of developing SSIs [14]. As obesity is a growing problem in Australia 
and other developed countries understanding the clinical effectiveness and cost-effectiveness 
of interventions for preventing SSIs in obese patients is important. Previous findings that 
NPWT may be cost-effective in the treatment of difficult-to-heal wounds do not necessarily 
support prophylactic use.  
Given the increasing prophylactic use of NPWT despite limited evidence of benefit, a study 
of the clinical effectiveness and cost-effectiveness of prophylactic NPWT is urgently 
required. One previous study constructed a decision-analytic model of prophylactic NPWT 
following caesarean section and concluded that it was not cost-effective, however that study 
was not limited to overweight patients and did not consider quality of life (QoL) [15]. In this 
study, our aim was to evaluate whether NPWT is cost-effective compared to standard care for 
the prevention of SSIs in obese women undergoing elective caesarean section. Obese women 
are at greater risk of SSI following caesarean section compared to women who are not 
overweight [16]. 
2.0 Methods 
2.1 Study Design 
We estimate the cost-effectiveness of NPWT compared to standard care, based on data from 
a pilot study of NPWT use in obese women following elective caesarean section. Cost-
effectiveness assessment was based on incremental cost (AU$) per SSI prevented and per 
quality-adjusted life year (QALY) gained. 
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The design of the pilot study has been described in detail elsewhere [17]. The pilot study was 
a prospective, single site randomised controlled trial (RCT). Obese (BMI>30kg/m2) women 
were recruited during the scheduled pre-operative visit before elective caesarean section 
booked prior to the commencement of labour. Informed consent was obtained from all 
patients. Randomisation occurred after recruitment and prior to surgery. Patients were 
allocated to two treatment arms in a 1:1 ratio using simple randomisation; NPWT PICOTM 
(disposable unit from Smith and Nephew, Hull, UK) (n=44) or standard care (n=43) which 
consisted of Comfeel Plus® dressing (Coloplast, Denmark). Data were collected on resource 
use, clinical outcomes and health-related QoL during the hospital stay and at weekly intervals 
for four weeks post-discharge. Total costs, SSI incidence and QALYs were compared across 
the two treatment arms and an incremental cost-effectiveness ratio (ICER) was calculated to 
describe the cost of additional QALYs gained by utilising NPWT for prophylaxis compared 
to standard care. 
2.2 Setting and Perspective 
The perspective taken was that of the public health care provider. The setting was the 
obstetrics unit of a large Australian tertiary teaching hospital. A standard surgical technique 
was used for all procedures but the treating health professionals were able to administer 
antibiotics or other medicines at their discretion. Follow-up occurred daily while the women 
were in hospital and via telephone once per week for four weeks post-discharge. No 
discounting was applied to costs or outcomes due to the short time horizon. 
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2.3 Data Collection 
Data describing in-hospital resource use and clinical outcomes were collected by direct 
observation or chart audit by a research assistant (RA) using report forms specifically 
developed for the trial. Data describing post-discharge resource use, clinical outcomes and 
QoL were collected during the weekly post-discharge telephone follow-ups with patients. 
The allocated dressings were applied by the operating obstetrician and their surgical assistant 
following wound closure. 
2.4 Resource Unit Costs 
Resources were valued in Australian dollars (AU$) at 2014 values (AU$1~ US$0.82 ~ €0.66 
at 17 December 2014). Resources recorded and their unit costs are given in Table 1. The total 
cost per resource was calculated for each patient by multiplying the per-unit cost of the 
resource by the number of units used. Each individual’s total cost of treatment was calculated 
as the sum of the individual’s total costs per resource over all resources. 
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Table 1: Unit Costs at 2014 Value 
Resource Unit Cost 
(AU$) 
Source 
INTERVENTIONS   
NPWT PICOTM Unit 180 Actual charge from Smith and 
Nephew 
Comfeel Plus ®  Dressing 5 Hospital estimate 
Nurse time to apply, change or 
remove NPWT or standard dressing 
(per hour) 
35 Queensland Health [18]  
HOSPITAL CARE   
Hospital stay for caesarean section 
without complications (per 6 day 
stay) 
10,191 National Efficient Price Determination 
2014-15 [19] 
Hospital stay for caesarean section 
without complications (per marginal 
day)1 
1,489 National Efficient Price Determination 
2014-15 [19] 
Adjustment for SSI treatment2 (per 
episode) 
380 National Efficient Price Determination 
2014-15 [19] 
POST-DISCHARGE CARE   
                                                          
1
 DRGv7.0 code O01C (caesarean delivery without catastrophic or serious complication/comorbidity). The 
NEPD 2014-15 provides inlier weights which apply to all lengths of stay between defined bounds (1-12 days in 
the case of O01C). For cost assignment we assumed that the full inlier weight applied to hospital stays of 6 days 
(the longest in our data set) and reduced the cost for shorter stays by the long-stay outlier per diem (assuming 
this to be the best estimate of the marginal cost of a day of hospitalisation). 
2
 DRGv7.0 code O01B (caesarean delivery with serious complication/comorbidity). 1.5 days were subtracted at 
the long-stay outlier per diem weight to account for the longer average length of stay with a complication. The 
adjustment is the difference between the resulting cost and the O01C cost. 
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Hospital stay for wound treatment 
following readmission (per 4 day 
stay) 
3,933 National Efficient Price Determination 
2014-15 [19] 
Hospital stay for wound treatment 
following readmission (per marginal 
day) 3 
780 National Efficient Price Determination 
2014-15 [19] 
General practitioner visit 37.50 Medicare Benefits Schedule 2014 [20] 
Emergency department visit 288 National Efficient Price Determination 
2014-15 [19] 
Other health specialist visit Varies Medicare Benefits Schedule 2014 [20] 
Medication Varies PBS Schedule 2014 [21] 
 
2.5 Outcome measures: SSI and Quality of Life 
SSI incidence measurement is described by REFERENCE REMOVED FOR BLINDING. 
[17]. Briefly, SSIs were assessed by an independent assessor blinded to treatment allocation 
in accordance with the Centres for Disease Control and Prevention definition [1]. Health 
related QoL data were collected using the SF-12v2® survey which is a multi-attribute health 
status classification system that assigns a single QoL index (utility weight) based on 
responses to 12 questions [22]. The SF-12v2® instrument was administered at baseline (prior 
to surgery) and at each of the four weekly post-discharge follow-ups. 
 
 
                                                          
3
 DRGv7.0 code T61B (postoperative and post-trauma infection without catastrophic or serious 
complication/comorbidity). Calculated the same way as a day in hospital for caesarean section, with the full 
inlier weight assigned to a 4 day length of stay. 
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2.6 Economic Analysis 
All patients had complete outcome (QALY) data and were included in the analysis. 
Descriptive statistics were used to describe resource use, costs and QoL. SF-12v2® QoL 
indices (utility weights) were calculated using the method of Brazier and Roberts [22]. 
QALYs were estimated from the utility weights using the standard area under the curve 
method. We assumed that the change from the baseline to the first post-discharge weight was 
linear and occurred over the period of hospitalisation, that the first post-discharge weight 
applied to the full first week following discharge and that the transition between post-
discharge weights was linear. Additional days at the fourth post-discharge weight were added 
where necessary to ensure an equal number of days were considered for each patient, 
regardless of length of hospital stay. QALYs were adjusted for differences in baseline SF-
12v2® indices using the regression-based adjustment of Manca, Hawkins and Sculpher [23].  
Data analysis was conducted using IBM SPSS Statistics for Windows 22 (IBM Corp, USA) 
[24] and Stata Statistical Software 13 (StataCorp, USA) [25]. When testing differences 
between means we used a Shapiro-Wilk test for the normality of the two distributions 
followed by an independent t-test or Mann-Whitney U test as appropriate. A Chi-square test 
or Fisher’s exact test was used for proportions. The differences in mean costs and outcomes 
between the two arms were used to estimate the ICER. A non-parametric bootstrap with 
1,000 replications was used to construct 95% percentile method confidence intervals (CIs) for 
the estimates.  
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2.7 Sensitivity Analysis 
The method chosen to construct QALYs from QoL weights for the base case analysis is 
described in 2.6. Arguably, the change in QoL over the hospital stay is too complex to be 
analysed with weights taken before and approximately 10 days after surgery. Consequently, it 
might be best to ignore the period of hospitalisation and consider only QALY differences 
between the two groups following discharge. Acknowledging this, we analysed only post-
discharge QALYs as a sensitivity analysis.  
3.0 Results 
3.1 Participant characteristics 
Table 2 shows summary statistics for the characteristics of the two treatment groups. As 
reported by REFERENCE REMOVED FOR BLINDING [17], patients receiving the 
standard treatment were more likely to smoke (p=0.032) and had longer average surgery time 
(p=0.002). They were also more likely to receive antibiotics post-surgery (p=0.021), typically 
due to surgeon concerns about potential complications.  
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Table 2: Summary of Descriptive Statistics for Treatment Groups 
 
Characteristic 
NPWT 
(n=44) 
Standard Dressing 
(n=43) 
 Mean ± SD   
Age (years)  30.61 ± 5.50 30.65 ± 5.00 
Baseline BMI 35.75 ± 4.58 36.81 ± 5.85 
Number of Previous CS 1.30 ± 0.95 1.26 ± 0.69 
Number of Other Comorbidities 0.73 ± 0.97 0.65 ± 0.78 
QoL Weight at Baseline 0.70 ± 0.13 0.70 ± 0.13 
Surgery Time (minutes)* 47.16 ± 12.50 57.26 ± 19.73 
 Number, %  
Patients who Smoke* 3, 7% 10, 23% 
Patients with Diabetes 0, 0% 4, 9% 
Patients with Gestational Diabetes 13, 30% 8, 19% 
Patients Receiving Prophylactic Antibiotics 
During Surgery 
38, 86% 31, 72% 
Patients Receiving Antibiotics Post-Surgery in 
Hospital* 
2, 5% 9, 21% 
Patients Receiving NSAIDs Post-Surgery in 
Hospital 
39, 89% 40, 93% 
Note: Table presents mean ± standard deviation, * indicates statistically significant difference 
at 5% significance level 
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3.2 Comparative Cost and Effectiveness Results 
Table 3 details the average resource use and costs for the treatment groups. For both groups, 
the cost of days in hospital accounted for the majority of the costs of treatment. 
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Table 3: Average Resource Use and Costs (per person) 
 NPWT (n=44) Standard Dressing (n=43) 
Item Avg. Use Avg. Cost ($) Avg. Use Avg. Cost ($) 
HOSPITAL CARE 
Hospital days 2.84 5,487.10 2.86 5,516.22 
Hospital readmission 
(events) 
0.02 89.40 0.02 55.19 
Hospital days following 
readmission 
0.09 0.05 
PICOTM units 1.02 184.09 0 0 
Comfeel Plus® dressing 0.02 0.11 1.12 5.60 
In-hospital SSI treatment 0.23 86.37 0.28 106.06 
Nurse labour for dressing 
change (minutes) 
8.27 4.83 1.28 0.74 
Nurse labour for dressing 
application (minutes) 
5.25 3.06 0.53 0.31 
POST-DISCHARGE CARE 
GP visits 0.25 9.38 0.74 27.91 
Emergency department 
visits 
0.02 6.55 0.05 13.40 
Midwife visits 0 0 0.07 5.65 
Post-discharge analgesics - 14.51 - 19.49 
Post-discharge antibiotics - 1.81 - 3.48 
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REFERENCE REMOVED FOR BLINDING reported the effectiveness of NPWT based on 
median outcomes [17]. Table 4 presents analysis comparison of outcomes focusing on the 
mean values which better reflects the requirements of an economic analysis [26]. There was 
no significant difference in SSI incidence or QALY per patient between the NPWT and 
standard dressing groups at the 5% level (Table 4). Nevertheless, the point estimates for SSI 
incidence and QALY per patient suggests that a larger sample size might find a statistically 
significant result favouring NPWT.  
Table 4: Components of Cost-Effectiveness Analyses 
 NPWT (n=44) Standard 
Dressing (n=43) 
Incremental difference 
[95%CI] 
Cost per Patient 
(mean ±SD)  (AU$) 
5,887.21 ± 
1,037.59 
5,754.04 ± 
1,483.93 
133.17 [-397.07, 690.79] 
SSI (proportion of 
patients) 
11/44 (25%) 15/43 (34.89%) 9.88% [-10.78%, 28.38%] 
QALYs per Patient 
(mean ±SD) 
0.069 ± 0.010 0.066 ± 0.010 0.0031 [-0.00037, 0.0067] 
ICER (AU$ per unit 
outcome) 
- - 1,347.36 per SSI prevented 
[-17,666.06, 41,873.49] 
 - - 42,339.87 per QALY  
[-275,040.40, 884,018.60] 
 
3.3 Cost-Effectiveness 
Table 4 also presents the comparative total costs and benefits and consequent ICERs. The 
ICERs are estimated to be AU$1,347 (95%CI dominant to $17,666) per SSI prevented and 
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$42,340 (95%CI dominant to $884,019) per QALY gained. However, the ICERs exhibit 
substantial uncertainty, as indicated by the very wide 95% CIs.  
The point estimate for incremental QALY gain may be an underestimation because the 
apparent gap between mean utility weights for the two treatment groups (which was 
statistically significant at week 3) had not closed at the fourth post-discharge follow-up 
(Table 5). If this difference persisted beyond the fourth week then the QoL benefits of 
prophylactic NPWT may be greater than reported. 
 
Table 5: Utility Weights at Each Post-Discharge Follow-Up 
Post-Discharge Follow-Up (* indicates 
statistically significant difference at 5% 
significance level) 
NPWT (n=44) Standard Dressing 
(n=43) 
1 0.70 ± 0.12 0.67 ± 0.13 
2 0.74 ± 0.14 0.71 ± 0.14 
3* 0.78 ± 0.12 0.72 ± 0.13 
4 0.78 ± 0.13 0.74 ± 0.12 
Note: Table presents mean ± standard deviation 
 
The cost-effectiveness plane (Figure 1) shows the considerable uncertainty in the incremental 
cost and QALY estimates. Since the majority of points are to the right of the y-axis, NPWT is 
likely to improve QoL, even if only by a small amount. Most of the points lie in the upper 
right quadrant, suggesting that NPWT increases costs while improving outcomes. The points 
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below the diagonal line suggest cost-effectiveness at a willingness-to-pay of AU$50,000 per 
QALY.  
 
Figure 1: Individual boostrap estimates of incremental cost and incremental effect with 
cost-effectiveness threshold of $50,000/QALY 
 
3.5 Sensitivity Analysis 
The ICER estimated excluding hospitalisation QALYs is $49,736 per QALY ( 95% CI -
$468,044 i.e. dominant to $1,001,493]. The ICER point estimate and area of uncertainty is 
similar to the base case, . suggesting that the inclusion or exclusion of the period of 
hospitalisation is not of great importance for the purpose of measuring incremental QALYs.  
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4.0 Discussion 
Our findings provide preliminary support for the hypothesis that NPWT is a cost-effective 
intervention for post-surgical wound management in obese women following elective 
caesarean section.  The point estimates suggest NPWT may be more costly than standard 
treatment but may also offer improvements in QoL and prevention of SSIs. This is clinically 
promising, although the pilot study’s small sample means the findings are statistically non-
significant and therefore inconclusive. The point (best available) estimate of the ICER is 
below (but close to) the rule-of-thumb threshold of AU$50,000 per QALY gained 
conventionally considered to represent good value for money in Australia [27]. The large 
confidence intervals highlight the small sample size and the challenges of assessing 
interventions with small changes in outcomes [28].   
A larger study might strengthen the evidence of NPWT’s cost effectiveness. Patients who 
developed SSIs in the pilot study had an average hospitalisation length of 2.96 days 
compared to 2.82 days for patients who did not develop SSIs (p=0.39). Consequently the cost 
assigned to developing an SSI is quite low. Other studies have reported median increases in 
length of stay of several days and consequently assign high costs (exceeding $3,000 in many 
cases) to SSIs [29, 30]. If more severe SSIs requiring longer hospital stays are observed in a 
larger trial and NPWT proves effective at reducing SSI incidence then the cost-effectiveness 
results may be more convincing. 
However, whilst there is a strong case for undertaking a full scale RCT to evaluate NPWT 
further and reduce the uncertainty around its clinical efficacy or cost, reducing the uncertainty 
around its cost-effectiveness will be hard to achieve. The pilot findings suggest NPWT may 
generate a very small QALY gain but for a small increased cost, with a lot of uncertainty in 
this small sample. The ratio of these two small numbers is giving an ICER near to the 
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commonly adopted $50,000 per QALY threshold. Whilst a change in QALY is desirable 
even if small,  it can make it hard to show cost-effectiveness with an acceptable level of 
certainty, even in a larger trial.  
Consequently, this pilot study provides important insights into the methods required to 
undertake a larger trial in this area. Using published guides on estimating sample size for 
cost-effectiveness analyses [31], it is possible to use the pilot findings to estimate the sample 
size required to show NPWT to be cost-effectiveness under the assumption of a willingness 
to pay threshold of $50,000 per QALY. A sample size of 175 participants would be needed 
per group to show a statistically significant difference of 0.003 QALYs (equivalent to 1.1 
days in full health), and 1,386 per group to show a difference of $133 in costs (80% power at 
the 95% confidence level). However, 109,190 participants would be needed per group to 
accept NPWT to be cost-effective with 95% confidence (power calculations assume expected 
correlation of -0.16 between difference in costs and difference in QALYs, standard deviation 
of $1,250 and 0.01 QALY in each group [31]). This number reduces to 1,666 per group if we 
choose a more lenient threshold of $100,000 per QALY. This estimate shows the difficulty in 
powering a study to reduce the uncertainty in cost-effectiveness (which is a ratio of two 
variables) rather than in just a single outcome measure, especially when the point estimate is 
so close to the maximum acceptable cost-effectiveness threshold. Therefore, any future trial 
would need to carefully consider the capacity to more sensitively capture any cost offsets 
from avoidance of SSI or QoL benefits associated with NPWT, for example with longer 
follow up. If the true QALY gain were 50% greater and the incremental costs were half that 
associated with NPWT in this pilot (0.0045 QALY and $66.50), the sample size reduces to 
1,257 or 316 per group for a threshold of $50,000 or $100,000 per QALY respectively.  
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4.1 Strengths and Limitations 
To our knowledge, this is the first RCT-based economic evaluation of prophylactic NPWT. 
Soares et al. [10] used data from a small pilot study; however, their evaluation was treatment 
focused as opposed to prophylactic. A previous pilot study reported some evidence of clinical 
effectiveness of prophylactic NPWT in obese women following caesarean section, however, 
that study used a weaker retrospective cohort design and did not evaluate cost-effectiveness 
[32]. A previous decision-analytic model of prophylactic NPWT following caesarean section 
concluded that prophylactic NPWT was not cost-effective [15]. That study considered only 
financial costs, which were also higher for NPWT in our study, and evaluated NPWT for all 
patients. The authors note that the greater risk of SSI in obese patients may mean 
prophylactic NPWT is cost-effective for that group.  
A small sample of only 87 patients is the greatest shortcoming of our study and means that 
the findings, while promising, are too uncertain to inform practice. Although our study 
suggests that NPWT may be cost-effective in this setting, there clearly remains a need for 
large studies before the clinical and cost-effectiveness of NPWT can be established. 
Similarly, the large confidence intervals around the estimates of incremental cost, effect and 
ICER emphasise that it is inappropriate to draw conclusions about cost-effectiveness from 
our sample. Our current study is underpowered and larger studies will be necessary to 
determine whether NPWT is cost-effective. 
There are a number of additional limitations, which should be considered in the design of a 
larger trial. Firstly, the 4 week follow-up period (which reflects the SSI definition) may have 
overlooked ongoing disparities in QoL (see Table 5). A further limitation is that the first post-
surgery QoL data collected was at the first post-discharge follow-up. This may have 
prevented us from accurately describing the difference in QoL experienced during the 
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hospital stay. Nevertheless, sensitivity analysis suggests that the complete exclusion of the 
time in hospital from the QALYs does not substantially change the result, so the precise 
treatment of QoL differences during the hospital stay may not be an issue of great 
importance. 
As noted by REFERENCE REMOVED FOR BLINDING [17] and seen in Table 2, the two 
treatment groups may not be comparable. Patients receiving standard treatment were more 
likely to smoke, had longer average surgery times and were more likely to receive 
prophylactic antibiotics after surgery. This raises the possibility that patients receiving 
standard treatment may have had more complicated surgeries. Additionally, since smoking is 
a recognised risk factor for SSI [14] the data may overestimate the benefit from NPWT. 
Alternatively, the higher proportion of patients with standard treatment receiving antibiotics 
post-surgery might lead to underestimation of the benefits of NPWT. We did not assign costs 
for surgery duration or prophylactic antibiotic use as these were not directly linked to the 
treatment received. A larger trial should be able to overcome the effects of heterogeneity in 
these factors with satisfactory randomisation. 
5.0 Conclusion 
This pilot study suggests NPWT may be cost-effective at preventing SSIs and improving 
patient QoL in obese women after a planned caesarean section. However, the findings from 
this small pilot study are not conclusive as they do not reach statistical significance.  The  
promising point estimates combined with the growing prophylactic use of NPWT in a clinical 
setting suggest that there may be value in conducting a larger study with greater power to 
evaluate the cost-effectiveness of NPWT in this setting. However, the point estimate ICER 
near the conventional threshold indicating value for money and the substantial uncertainty 
observed in this pilot suggest this might be challenging to achieve.  This study provides 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
important insights into methodological considerations for the larger trial in order to 
demonstrate cost-effectiveness. 
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• Cost-effectiveness study of prophylactic NPWT post caesarean section in obese 
women 
• Pilot compared costs alongside QoL and SSI incidence as outcome measures 
• NPWT may be cost-effective; however, results do not reach statistical significance 
• There is a need for larger trials to reduce uncertainty and confirm findings 
• Sensitive capture of QoL and cost offsets are paramount to show cost-effectiveness 
 
